Please enable JavaScript to continue using this application.

Compare $CADL vs $IMDX | Chartloom

Compare

$CADL vs $IMDX

Candel Therapeutics Inc · Insight Molecular Diagnostics Inc

CADL

Candel Therapeutics Inc

IMDX

Insight Molecular Diagnostics Inc

Compare $CADL vs $IMDX

Comparing Candel Therapeutics Inc and Insight Molecular Diagnostics Inc

CADLCandel Therapeutics Inc

IMDXInsight Molecular Diagnostics Inc

CADLCandel Therapeutics Inc

Market cap

$728M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

82.7%

52W performance

57.8%

FCF yield

-7.9%

IMDXInsight Molecular Diagnostics Inc

Market cap

$109M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

58.81x

Rev growth (TTM)

-60.8%

YTD performance

-52.9%

52W performance

-8.4%

FCF yield

-28.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CADL

IMDX

Detailed metrics comparison

CADL

Candel Therapeutics Inc

IMDX

Insight Molecular Diagnostics Inc

Market Cap

CADL$728M

IMDX$109M

Enterprise Value

CADL$575M

IMDX$92M

Price

CADL$9.94

IMDX$3.37

P/E Ratio

CADLN/A

IMDXN/A

P/S Ratio

CADL6,281.93x

IMDX65.16x

EV/Sales

CADL5,042.14x

IMDX54.99x

EV/EBITDA

CADL0.00x

IMDX0.00x

P/B Ratio

CADL6.18x

IMDX102.52x

P/FCF Ratio

CADLN/A

IMDXN/A

EV/FCF

CADL-10.02x

IMDX-2.97x

PEG Ratio

CADLN/A

IMDXN/A

Forward P/E (NTM)

CADLN/A

IMDXN/A

Forward P/S (NTM)

CADLN/A

IMDX58.81x

Revenue (TTM)

CADL$0

IMDX$2M

Revenue Growth (YoY)

CADLN/A

IMDX-60.8%

Forward Rev Growth

CADL371.1%

IMDX593.7%

Gross Margin (TTM)

CADL0.0%

IMDX48.3%

Operating Margin (TTM)

CADL0.0%

IMDX0.0%

EBITDA Margin (TTM)

CADL0.0%

IMDX-1986.2%

Net Margin (TTM)

CADL0.0%

IMDX-2955.6%

FCF Margin (TTM)

CADLN/A

IMDX-1848.8%

Net Income (TTM)

CADL$-89M

IMDX$-49M

FCF (TTM)

CADL$-57M

IMDX$-31M

EPS (TTM)

CADL-$1.19

IMDX-$1.34

ROE (TTM)

CADL-8938.0%

IMDX-42668.0%

ROA (TTM)

CADL-5631.0%

IMDX-14147.0%

ROIC (TTM)

CADL-6512.0%

IMDX-37415.0%

Cash

CADL$202M

IMDX$18M

Debt

CADL$48M

IMDX$766K

Net Cash/Debt

CADL$154M

IMDX$17M

Current Ratio (TTM)

CADL16.09x

IMDX2.00x

Quick Ratio (TTM)

CADL15.89x

IMDX1.82x

Debt/Equity (TTM)

CADL0.38x

IMDX0.92x

Debt/Assets (TTM)

CADL0.0%

IMDX0.0%

Interest Coverage (TTM)

CADLN/A

IMDXN/A

Net Debt/EBITDA (TTM)

CADL0.00x

IMDX0.00x

Beta

CADL-0.28

IMDX1.86

52W Performance

CADL57.8%

IMDX-8.4%

YTD Performance

CADL82.7%

IMDX-52.9%

% from 52W High

CADL-29.0%

IMDX-60.4%

% from 52W Low

CADL128.5%

IMDX39.3%

Asset Turnover (TTM)

CADL0.00x

IMDX0.05x

FCF Yield (TTM)

CADL-7.9%

IMDX-28.4%

Earnings Yield (TTM)

CADL-12.2%

IMDX-45.4%

Dividend Yield (TTM)

CADLN/A

IMDXN/A

Rule of 40

CADL0.0

IMDX-1,909.6

EV/GP/RG

CADLN/A

IMDX10.54

Ticker research

View CADL research View IMDX research

Metric	CADL Candel Therapeutics Inc	IMDX Insight Molecular Diagnostics Inc
Market & Valuation
Market Cap	$728M	$109M
Enterprise Value	$575M	$92M
Price	$9.94	$3.37
P/E Ratio	N/A	N/A
P/S Ratio	6,281.93x	65.16x
EV/Sales	5,042.14x	54.99x
EV/EBITDA	0.00x	0.00x
P/B Ratio	6.18x	102.52x
P/FCF Ratio	N/A	N/A
EV/FCF	-10.02x	-2.97x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	58.81x
Revenue & Growth
Revenue (TTM)	$0	$2M
Revenue Growth (YoY)	N/A	-60.8%
Forward Rev Growth	371.1%	593.7%
Profitability
Gross Margin (TTM)	0.0%	48.3%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-1986.2%
Net Margin (TTM)	0.0%	-2955.6%
FCF Margin (TTM)	N/A	-1848.8%
Net Income (TTM)	$-89M	$-49M
FCF (TTM)	$-57M	$-31M
EPS (TTM)	-$1.19	-$1.34
ROE (TTM)	-8938.0%	-42668.0%
ROA (TTM)	-5631.0%	-14147.0%
ROIC (TTM)	-6512.0%	-37415.0%
Financial Health
Cash	$202M	$18M
Debt	$48M	$766K
Net Cash/Debt	$154M	$17M
Current Ratio (TTM)	16.09x	2.00x
Quick Ratio (TTM)	15.89x	1.82x
Debt/Equity (TTM)	0.38x	0.92x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.28	1.86
52W Performance	57.8%	-8.4%
YTD Performance	82.7%	-52.9%
% from 52W High	-29.0%	-60.4%
% from 52W Low	128.5%	39.3%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.05x
FCF Yield (TTM)	-7.9%	-28.4%
Earnings Yield (TTM)	-12.2%	-45.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-1,909.6
EV/GP/RG	N/A	10.54
Ticker research	View CADL research	View IMDX research

Valuation

P/S Ratio

IMDX

65.16x

CADL

6,281.93x

EV/FCF

CADL

-10.02x

IMDX

-2.97x

Growth & revenue

Revenue Growth TTM

IMDX

-60.8%

Forward Revenue Growth

IMDX

593.7%

CADL

371.1%

Profitability & performance

Gross Margin

IMDX

48.3%

CADL

0.0%

ROE

CADL

-8938.0%

IMDX

-42668.0%

FCF Yield %

CADL

-7.9%

IMDX

-28.4%

52-Week Performance

CADL

57.8%

IMDX

-8.4%

Detailed metrics comparison

CADL

Candel Therapeutics Inc

IMDX

Insight Molecular Diagnostics Inc

Market Cap

CADL$728M

IMDX$109M

Enterprise Value

CADL$575M

IMDX$92M

Price

CADL$9.94

IMDX$3.37

P/E Ratio

CADLN/A

IMDXN/A

P/S Ratio

CADL6,281.93x

IMDX65.16x

EV/Sales

CADL5,042.14x

IMDX54.99x

EV/EBITDA

CADL0.00x

IMDX0.00x

P/B Ratio

CADL6.18x

IMDX102.52x

P/FCF Ratio

CADLN/A

IMDXN/A

EV/FCF

CADL-10.02x

IMDX-2.97x

PEG Ratio

CADLN/A

IMDXN/A

Forward P/E (NTM)

CADLN/A

IMDXN/A

Forward P/S (NTM)

CADLN/A

IMDX58.81x

Revenue (TTM)

CADL$0

IMDX$2M

Revenue Growth (YoY)

CADLN/A

IMDX-60.8%

Forward Rev Growth

CADL371.1%

IMDX593.7%

Gross Margin (TTM)

CADL0.0%

IMDX48.3%

Operating Margin (TTM)

CADL0.0%

IMDX0.0%

EBITDA Margin (TTM)

CADL0.0%

IMDX-1986.2%

Net Margin (TTM)

CADL0.0%

IMDX-2955.6%

FCF Margin (TTM)

CADLN/A

IMDX-1848.8%

Net Income (TTM)

CADL$-89M

IMDX$-49M

FCF (TTM)

CADL$-57M

IMDX$-31M

EPS (TTM)

CADL-$1.19

IMDX-$1.34

ROE (TTM)

CADL-8938.0%

IMDX-42668.0%

ROA (TTM)

CADL-5631.0%

IMDX-14147.0%

ROIC (TTM)

CADL-6512.0%

IMDX-37415.0%

Cash

CADL$202M

IMDX$18M

Debt

CADL$48M

IMDX$766K

Net Cash/Debt

CADL$154M

IMDX$17M

Current Ratio (TTM)

CADL16.09x

IMDX2.00x

Quick Ratio (TTM)

CADL15.89x

IMDX1.82x

Debt/Equity (TTM)

CADL0.38x

IMDX0.92x

Debt/Assets (TTM)

CADL0.0%

IMDX0.0%

Interest Coverage (TTM)

CADLN/A

IMDXN/A

Net Debt/EBITDA (TTM)

CADL0.00x

IMDX0.00x

Beta

CADL-0.28

IMDX1.86

52W Performance

CADL57.8%

IMDX-8.4%

YTD Performance

CADL82.7%

IMDX-52.9%

% from 52W High

CADL-29.0%

IMDX-60.4%

% from 52W Low

CADL128.5%

IMDX39.3%

Asset Turnover (TTM)

CADL0.00x

IMDX0.05x

FCF Yield (TTM)

CADL-7.9%

IMDX-28.4%

Earnings Yield (TTM)

CADL-12.2%

IMDX-45.4%

Dividend Yield (TTM)

CADLN/A

IMDXN/A

Rule of 40

CADL0.0

IMDX-1,909.6

EV/GP/RG

CADLN/A

IMDX10.54

Ticker research

View CADL research View IMDX research

Metric	CADL Candel Therapeutics Inc	IMDX Insight Molecular Diagnostics Inc
Market & Valuation
Market Cap	$728M	$109M
Enterprise Value	$575M	$92M
Price	$9.94	$3.37
P/E Ratio	N/A	N/A
P/S Ratio	6,281.93x	65.16x
EV/Sales	5,042.14x	54.99x
EV/EBITDA	0.00x	0.00x
P/B Ratio	6.18x	102.52x
P/FCF Ratio	N/A	N/A
EV/FCF	-10.02x	-2.97x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	58.81x
Revenue & Growth
Revenue (TTM)	$0	$2M
Revenue Growth (YoY)	N/A	-60.8%
Forward Rev Growth	371.1%	593.7%
Profitability
Gross Margin (TTM)	0.0%	48.3%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-1986.2%
Net Margin (TTM)	0.0%	-2955.6%
FCF Margin (TTM)	N/A	-1848.8%
Net Income (TTM)	$-89M	$-49M
FCF (TTM)	$-57M	$-31M
EPS (TTM)	-$1.19	-$1.34
ROE (TTM)	-8938.0%	-42668.0%
ROA (TTM)	-5631.0%	-14147.0%
ROIC (TTM)	-6512.0%	-37415.0%
Financial Health
Cash	$202M	$18M
Debt	$48M	$766K
Net Cash/Debt	$154M	$17M
Current Ratio (TTM)	16.09x	2.00x
Quick Ratio (TTM)	15.89x	1.82x
Debt/Equity (TTM)	0.38x	0.92x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.28	1.86
52W Performance	57.8%	-8.4%
YTD Performance	82.7%	-52.9%
% from 52W High	-29.0%	-60.4%
% from 52W Low	128.5%	39.3%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.05x
FCF Yield (TTM)	-7.9%	-28.4%
Earnings Yield (TTM)	-12.2%	-45.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-1,909.6
EV/GP/RG	N/A	10.54
Ticker research	View CADL research	View IMDX research